Northwire Canada EditionSunday, July 12, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Production / Operations

PharmAla Signs Supply & Data Agreement with Nautilus Sanctuary for Phase 2 MDMA Clinical Trial Treating Post-Traumatic Stress and Adjustment Disorder in Frontline Healthcare Workers and First Responders

By The Northwire Desk — AI Analysis Mar 03, 2026 · 09:00 MDMA · 0.095 Pharmala Biotech Holdings Inc.
MDMA · Price

Executive Summary

  • PharmAla Biotech executed a Supply & Data Agreement with Nautilus Sanctuary to provide LaNeo™ MDMA for a Phase 2 open‑label trial targeting PTSD in frontline healthcare workers and first responders.
  • In exchange, PharmAla receives a perpetual, non‑exclusive license to the de‑identified clinical trial data, which can be used for regulatory filings and commercial purposes worldwide.
  • The company also completed shipment of LaNeo™ MDMA to University College London for an earlier announced clinical trial, underscoring its role as a primary supplier of clinical‑grade MDMA.

Key Details

  • Agreement Parties: PharmAla Biotech Holdings Inc. (CSE: MDMA) and Nautilus Sanctuary Inc., Brooklyn, NY.
  • Product Supplied: LaNeo™ MDMA (clinical‑grade MDMA).
  • Trial Description: Open‑label Phase 2 study – “An Open Label Study to Treat Post‑Traumatic Stress in Frontline Healthcare Workers and First Responders Using MDMA‑Assisted Therapy.”
  • License Granted to PharmAla: Perpetual, non‑exclusive right to use the Clinical Trial Data (pseudonymized, de‑identified raw data sets and analysis of safety/efficacy) for regulatory approvals and any commercial purpose in all jurisdictions.
  • Strategic Rationale: Supply‑for‑data model creates value by securing proprietary clinical evidence without cash outlay; supports PharmAla’s pipeline and potential future commercialization of LaNeo™ MDMA.
  • Additional Shipment: Completed delivery of LaNeo™ MDMA to University College London (UCL) for a previously announced clinical trial, reinforcing supply chain capabilities.
  • Quotes:
  • “This agreement represents a continuation of our innovative supply‑for‑data model… the clinical data generated … will be an important addition to our growing portfolio of clinical evidence supporting the safety and efficacy of LaNeo™ MDMA.” – Nicholas Kadysh, CEO, PharmAla Biotech.

Notable Quotes

  • “We deeply appreciate PharmAla’s donation of LaNeo MDMA to our study… Their generosity helps accelerate important clinical research…” – Dr. Willa Hall, President, Nautilus Sanctuary.
Read the original news release →

More from Pharmala Biotech Holdings Inc.

May 20, 2026 · 08:15

PharmAla’s ALA-002 draws a nine-figure pact with Nasdaq-listed Jupiter, signalling Big Pharma-style validation for next-gen MDMA in a transformed U.S. regulatory landscape.

Other May 20, 2026 · 07:38

PharmAla’s $100M-Plus ALA-002 Licensing Pact with Nasdaq’s Jupiter Validates Next-Gen MDMA, Fueling a Pivotal Re-Rating

M&A / Property May 13, 2026 · 08:30

PharmAla Advances APA-01 SPV Deal; Royalty Stream Contingent on Funding

M&A / Property Apr 27, 2026 · 08:00

PharmAla Biotech Monetizes APA-01 IP via SPV Amidst Psychedelic Regulatory Tailwinds

Other Apr 21, 2026 · 16:05

PharmAla Biotech Gains on Regulatory Tailwinds as Earnings Confirm Growth Amidst Management Shake-Up

Earnings Apr 20, 2026 · 08:15

CSE: MDMA

Production / Operations